Biopharmaceutical CMO and CRO Market by Source (Mammalian and Non-Mammalian), Service Type (Contract Manufacturing and Contract Research), Product (Biologics and Biosimilars): Global Market Size Estimates and Forecast (2022-2030)

Code: BMIRE00026789 | Pages: 100 | Industry: Healthcare IT | Date: Oct 2022 | Type: Global

The market crossed US$ 32.25 billion in 2022 and is expected to hit US$ 54.13 billion by 2030, recording a CAGR of 6.5% during the forecast period

The mammalian segment is expected to be growing due to associated benefits

The rising significance of mammalian cell structures in research studies facilitates the development of new vaccines, therapies, antibodies, and proteins in the biopharmaceutical industry. Their abilities to add human-like post-translational modifications to complex protein therapeutics and recent developments in this segment lead to more productive and efficient biologics manufacturing using mammalian cells. As per the study published in the National Library of Medicine (NLM), in the past 3–4 years, 62 of the 71 new biopharmaceutical active ingredients in the market were recombinant proteins, and of those, 52 (84%) were from mammalian cells, one from a transgenic system, five from E. coli, and four from S. cerevisiae.

Within the report, the market is segmented into the source, service type, product, and geography. Based on the source, global biopharmaceutical CMO and CRO market are segmented into mammalian and non-mammalian. Based on service type, the market is divided into contract manufacturing and contract research. By product, market segmentation is biologics and biosimilars. Geographically, the market is sub-segmented into North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa.

Increasing expenditure on R&D and outsourcing activities

Pharmaceutical and biotech companies focus on R&D activities to innovate new molecules and therapeutic platforms to deal with chronic diseases and rare ailments; they also extensively invest in R&D activities to develop various therapeutic applications with strong medical and commercial potential. The research-based pharmaceutical industry is essential in restoring Europe to growth and ensuring future competitiveness in an advancing global economy. In 2020 it funded an estimated € 39,000 million in R&D in Europe. Moreover, according to a study published by Pharmaceutical Research and Manufacturers of America (PhRMA), the R&D expenditure of biopharmaceutical companies grew from US$ 49.6 billion in 2012 to US$ 79.6 billion in 2018. Such massive investments in R&Ds are likely to drive the contract research organization services market during the forecast period.

The rising biosimilars and biologics usage due to associated efficacy and safety

The efficacy and safety of biotherapeutics associated with the ability to treat various untreatable diseases are majorly driving the growth of biosimilars and biologics. Technological advancement and significant improvement in the understanding of diseases such as cancer and rheumatoid arthritis are creating a demand for the development of biosimilars and biologics. Biologics are large complex molecules, up to 1,000 times the size of small molecule generic drugs. To save the in-house cost and time required for these testing services throughout the development process of the biologics and biosimilars in the initial stages, the companies prefer to outsource these services to the pre-clinical CROs.

Recent strategic developments in the biopharmaceutical CMO and CRO market

The biopharmaceutical CMO and CRO market has undergone several significant developments, and a few of these have been mentioned below:

  • In December 2020, the global biopharmaceutical contract development and manufacturing organization (CDMO), AGC Biologics, announced to expand production capacity of its Copenhagen (Denmark) facility. This expansion will more than double AGC Biologics’ single-use bioreactor mammalian cell culture
  • In November 2021, Lonza announced the acquisition of the Exosomics Service Unit. Lonza will access expertise and capabilities in extracellular vesicle (EV) analytics and characterization. This acquisition will strengthen its position as a leading global CDMO in exosome bioprocessing

The biopharmaceutical CMO and CRO market is driven by several players by implementing strategic activities such as investments, new launches, mergers & acquisitions, and partnerships. AGC Biologics; Boehringer Ingelheim International GmbH; FUJIFILM Diosynth Biotechnologies U.S.A., Inc; TOYOBO CO., LTD; JRS PHARMA; Lonza; PRA Health Sciences, Inc; ProBioGen AG; Rentschler Biopharma SE; Samsung BioLogics among the prominent players operating in the market.

The target audience for the report:

  • Raw Material Providers
  • Associations, Organizations, Forums, And Alliances
  • Government Bodies, Such as Regulating Authorities and Policymakers
  • Medical Device Companies
  • Pharmaceutical and Biopharmaceutical Companies
  • Venture Capitalists, Private Equity Firms, and Start-Up Companies
  • Research Institutes, Organizations, and Consulting Companies

Scope of the report:

In this report, the market has been segmented based on:

  • Source:
  • Mammalian
  • Non-Mammalian
  • Service Type:
  • Contract Manufacturing
  • Contract Research
  • Product:
    • Biologics
    • Biosimilars
  • Region:
    • North America
    • Europe
    • Asia Pacific
    • South & Central America
    • Middle East & Africa
  • Companies Profiled
    • AGC Biologics
    • Boehringer Ingelheim International GmbH
    • FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
    • TOYOBO CO., LTD
    • JRS PHARMA
    • Lonza
    • PRA Health Sciences, Inc.
    • ProBioGen AG
    • Rentschler Biopharma SE
    • Samsung BioLogics

The List of Companies
- AGC Biologics
- Boehringer Ingelheim International GmbH
- FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
- TOYOBO CO., LTD
- JRS PHARMA
- Lonza
- PRA Health Sciences, Inc.
- ProBioGen AG
- Rentschler Biopharma SE
- Samsung BioLogics

Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title
Company
Requirement

Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.


Purchase Options
Single User License
$2000
Site License
$3000
Enterprise License
$4000